Literature DB >> 2043283

A comparative review of the adverse effects of treatments for hyperlipidaemia.

A Steiner1, B Weisser, W Vetter.   

Abstract

Various lipid-lowering drugs have been shown to reduce serum cholesterol and serum triglycerides effectively. In view of trials indicating that lipid-lowering drugs may reduce cardiac morbidity and mortality but not the overall mortality in the study group, increased attention must be focused on potential harmful side effects during treatment with these agents. The adverse effects of many of the principal drugs in this category are discussed. Gastrointestinal symptoms, usually self-limited and reversible, are the most common side effects. Potential harmful adverse effects include drug interactions (cholestyramine), myopathy and hepatic injury (HMG-CoA reductase inhibitors), and increased gallstone formation and ventricular arrhythmias (clofibrate). Not all lipid-lowering drugs have been studied adequately on a long term basis, so that medications given for an indefinite period must be reevaluated frequently. However, there are several agents that lower serum lipid levels effectively and that have been used for more than 20 years without serious side effects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2043283     DOI: 10.2165/00002018-199106020-00003

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  107 in total

1.  The effect of cholestyramine on intestinal absorption.

Authors:  R J West; J K Lloyd
Journal:  Gut       Date:  1975-02       Impact factor: 23.059

2.  Safety and efficacy of probucol during one year of administration.

Authors:  D T Nash
Journal:  J Clin Pharmacol       Date:  1974 Aug-Sep       Impact factor: 3.126

3.  The influence of cholestyramine on thyroxine absorption.

Authors:  R C Northcutt; J N Stiel; J W Hollifield; E G Stant
Journal:  JAMA       Date:  1969-06-09       Impact factor: 56.272

Review 4.  Pathogenesis and management of lipoprotein disorders.

Authors:  E J Schaefer; R I Levy
Journal:  N Engl J Med       Date:  1985-05-16       Impact factor: 91.245

5.  Mechanisms of hypolipidemic action of nicotinic acid.

Authors:  B J Kudchodkar; H S Sodhi; L Horlick; D T Mason
Journal:  Clin Pharmacol Ther       Date:  1978-09       Impact factor: 6.875

6.  Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriocslerosis.

Authors:  A M Gotto; E L Bierman; W E Connor; C H Ford; I D Frantz; C J Glueck; S M Grundy; J A Little
Journal:  Circulation       Date:  1984-05       Impact factor: 29.690

7.  Possible association of granulomatous hepatitis with clofibrate therapy.

Authors:  E H Pierce; D L Chesler
Journal:  N Engl J Med       Date:  1978-08-10       Impact factor: 91.245

8.  Effects of gemfibrozil on serum lipids.

Authors:  P Samuel
Journal:  Am J Med       Date:  1983-05-23       Impact factor: 4.965

9.  Lipids, diabetes, and coronary heart disease: insights from the Framingham Study.

Authors:  W B Kannel
Journal:  Am Heart J       Date:  1985-11       Impact factor: 4.749

10.  Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man.

Authors:  S M Grundy; H Y Mok; L Zech; M Berman
Journal:  J Lipid Res       Date:  1981-01       Impact factor: 5.922

View more
  8 in total

1.  Effect of clofibrate in jaundiced term newborns.

Authors:  Ashraf Mohammadzadeh; A Sh Farhat; R Iranpour
Journal:  Indian J Pediatr       Date:  2005-02       Impact factor: 1.967

Review 2.  Drug-induced gallbladder disease. Incidence, aetiology and management.

Authors:  P P Michielsen; H Fierens; Y M Van Maercke
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

3.  Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. The French-Dutch Fluvastatin Study Group.

Authors:  B Jacotot; J D Banga; P Pfister; M Mehra
Journal:  Br J Clin Pharmacol       Date:  1994-09       Impact factor: 4.335

4.  Efficacy and safety of fluvastatin in women with primary hypercholesterolaemia.

Authors:  T K Peters; E N Muratti; M Mehra
Journal:  Drugs       Date:  1994       Impact factor: 9.546

5.  The Effect of Clofibrate on Decreasing Serum Bilirubin in Healthy Term Neonates under Home Phototherapy.

Authors:  Reza Sharafi; Zhaleh Mortazavi; Simin Sharafi; Reza Moradi Parashkouh
Journal:  Iran J Pediatr       Date:  2010-03       Impact factor: 0.364

Review 6.  Optimal lipid modification: the rationale for combination therapy.

Authors:  James M Backes; Cheryl A Gibson; Patricia A Howard
Journal:  Vasc Health Risk Manag       Date:  2005

7.  Correlation of neomycin, faecal neutral and acid sterols with colon carcinogenesis in rats.

Authors:  S K Panda; S C Chattoraj; S A Broitman
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

Review 8.  The Effects of Clofibrate on Neonatal Jaundice: A Systematic Review.

Authors:  Fathemeh Eghbalian; Ali Hasanpour-Dehkordi; Roya Raeisi
Journal:  Int J Prev Med       Date:  2022-01-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.